Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 11, 2015, Pages 1727-1734

  Rafique, Zubaid ^a   Peacock, William Frank ^a   Lovecchio, Frank ^b   Levy, Phillip D ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hyperkalemia; Potassium; Renin angiotensin aldosterone system; Sodium zirconium cyclosilicate; ZS 9

Indexed keywords

POTASSIUM; SODIUM ZIRCONIUM CYCLOSILICATE; MINERALOCORTICOID ANTAGONIST; SILICATE; ZS-9 COMPOUND;

ARTICLE; CATION EXCHANGE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HUMAN; HYPERKALEMIA; HYPOKALEMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINE PH; ANIMAL; CHEMISTRY; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HEART FAILURE;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN-ANGIOTENSIN SYSTEM; SILICATES;

EID: 84936953045     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1066334     Document Type: Article

References (26)

1. Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci 2014;10(2):251-7
2. An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Critical Care 2012;16(6):R225
3. Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4(3):542-51
4. Mahoney BA, Smith WA, Lo DS, et al. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev 2005;18(2):CD003235
5. Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (kayexalate) use: a systematic review. Am J Med 2013;126(3):264e9-24
6. Palmer B. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2014;351:585-92
7. Dixon BS. Zirconium Cyclosilicate for treatment of Hyperkalemia. JAMA 2014;312(21):2117-18
8. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010;21(5):733-5
9. Ahn SY, Ryu J, Baek SH, et al. Incident chronic kidney disease and newly developed complications related to renal dysfunction in an elderly population during 5 years: a community-based elderly population cohort study. PLoS One 2013;8(12):e84467
10. Vardeny O, Claggett B, Anand I, et al. Incidence, predictors, and outcomes related to hypo-and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014;7(4):573-9
11. Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis 2010;56(2):387-93
12. St Peter WL, Odum LE, Whaley-Connel AT. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy 2013;33(5):496-514
13. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012;7(8):1234-41
14. Rossignol P, Dobre D, McMurray J, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Circ Heart Fail 2014;7(1):51-8
15. Jain N, Kotla S, Little B, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012;109(10):1510-13
16. Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One 2014;9(12):e114686
17. Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggest that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int 2015. [Epub ahead of print]
18. Roger SD, Rasmussen HS, Lavin PT, et al. Effect of ZS-9 on serum bicarbonate and BUN in a Phase 3 randomized, double-blind, placebo-controlled trial. Am Soc Nephrol Kidney Week 2014;abstract 2743
19. Singh B, Ash SR, Lavin PT, et al. Effect of ZS-9 on serum bicarbonate and BUN in a phase 3 randomized, double-blind, placebo-controlled trial [abstract SP251]. 1st European Renal Association and European Dialysis and Transplant Association Congress; 2014
20. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372(3):222-31
21. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia. JAMA 2014;312(21):2223-33
22. Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 2015. [Epub ahead of print]
23. Echemann M, Zannad F, Briancon S, et al. Determinants of angiotensinconverting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J 2000;139:624-31
24. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Card 1997;59(7):7-10
25. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? Am Geriatr Soc 2002;50:1297-300
26. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-92